Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Review article: Biomedical intelligence

Vol. 140 No. 3536 (2010)

Chronic age-related diseases share risk factors: do they share pathophysiological mechanisms and why does that matter?

  • Nicole M. Probst-Hensch
DOI
https://doi.org/10.4414/smw.2010.13072
Cite this as:
Swiss Med Wkly. 2010;140:w13072
Published
30.08.2010

Summary

The World Health Organization (WHO) assigns high priority to the prevention of non-communicable age-related diseases such as heart disease, cancer, diabetes, stroke and chronic lower respiratory diseases. They are now the leading causes of death, in both industrialised and developing countries, mostly due to increased life expectancy and urbanisation with associated changes in lifestyle and environment. Tobacco smoking, physical inactivity and resulting obesity are established risk factors for many chronic diseases. Yet, the aetiology of age-related diseases is complex and varies between individuals. This often makes it difficult to identify causal risk factors, especially if their relative effects are weak. For example, the associations of both obesity and air pollution with several age-related diseases remain poorly understood with regard to causality and biological mechanisms. Exposure to both, excess body fat and particulate matter, is accompanied by systemic low-grade inflammation as well as alterations in insulin/insulin-like growth factor signalling and cell cycle control. These mechanisms have also been associated in animal and some human studies with longevity and ageing in more general terms. In this paper, it is therefore hypothesised that they may, at least in part, be responsible for the adverse health effects of obesity and air pollution. It is argued that molecular and genetic epidemiology now offer novel instruments to improve the understanding of these pathophysiological pathways and their link to disease aetiology. Understanding the causality of exposure disease associations and differences in susceptibilities to environment and lifestyle is an important aspect for effective prevention.

References

  1. World Health Organization. 2008–2013 Action plan for the global strategy for the prevention and control of non-communicable diseases. WHO Press, Geneva, Switzerland 2008. http://www.who.int/nmh/publications/ncd_action_plan_en.pdf
  2. Preventing chronic diseases: a vital investment - WHO global report. Geneva: World Health Organization, 2005.
  3. Khoury MJ, Wacholder S. Invited commentary – from genome-wide association studies to genome-environment-wide interactions studies – challenges and opportunities. Am J Epidemiol. 2009;169:227–30.
  4. Fallin MD, Matteini. Genetic epidemiology in aging research. J Gerontol A Biol Sci Med Sci. 2009;64:47–60.
  5. Ebrahim S, Davey Smith G. Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology? Hum Genet. 2008;123:15–33.
  6. Davies RM, Wagner EG, Groves T. Advances in managing chronic disease. BMJ. 2000;320:525–6.
  7. Cluett C, Melzer D. Human genetic variations: beacons on the pathways to successful ageing. Mech Ageing Dev. 2009;130(9):553–63.
  8. Wolfson M, Budovsky A, Tacutu R, Fraifeld V. The signaling hubs at the crossroad of longevity and age-related disease networks. Int J Biochem Cell Biol. 2009;41(3):516–20.
  9. Thomas A. Identifying and preventing diseases in an ageing world. Maturitas. 2010;65:85–6.
  10. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer. 2007;121(4):856–62.
  11. Roe CM, Fitzpatrick AL, Xiong C, Sieh W, Kuller L, Miller JP, et al. Cancer linked to Alzheimer disease but not vascular dementia. Neurology. 2010;74(2):106–12.
  12. Barabasi AL. Network medicine – from obesity ot the "diseasome”. N Engl J Med. 2007;357(4):404–7.
  13. Go K-I, Cusick ME, Valle D, Childs B, Vidal M, Barabasi AL. The human disease network. PNAS. 2007;104(21):8685–90.
  14. Wyatt SB, Winters KP, Dubbert PM. Overweight and obesity: prevalence, consequences, and causes of a growing public health problem. Am J Med Sci. 2006;331:166–74.
  15. Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 2006;355(8):763–78.
  16. De Laet C, Kanis JA, Odén A, Johanson H, Johnell O, Delmas P, et al. Body mass index as a predictor of fracture risk: A meta-analysis. Osteoporos Int. 16:1330–8.
  17. Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357(8):753–61.
  18. Teucher B, et al. Obesity- Focus on all-cause mortality and cancer. Maturitas. 2010:65:112–6.
  19. Nejat EJ, et al. Predictors of chronic disease at midlife and beyond – the health risks of obesity. Maturitas. 2010:65:106–11.
  20. Fontana L. The scientific basis of caloric restriction leading to longer life. Curr Opin Gastroenterol. 2009;25:114–50.
  21. Melnik BC. Permanent impairment of insulin resistance from pregnancy to adulthood: the primary basic risk factor of chronic Western diseases. Medical Hypotheses. 2009;73:670–81.
  22. Loh WJ, North BV, Johnston DG, Godsland IF. Insulin resistance-related biomarker clustering and subclinical inflammation as predictors of cancer mortality during 21.5 years of follow-up. Cancer Causes Control 2010;21:709–18.
  23. Bastard J-P, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17(1):4–12.
  24. Long VD, Fontana L. Calorie restriction and cancer prevention: metabolic and molecular mechanisms. Trends in Pharmacological Science. 2010;31:89–98.
  25. Karrasch S, Holz O, Jörres RA. Aging and induced senescence as factors in the pathogenesis of lung emphysema. Resp Med. 2008;102:1215–30.
  26. Vasto S, Candore G, Balistreri CR, Caruso M, Colonna-Romano G, Grimalidi MP, et al. Inflammatory networks in ageing, age-related diseases and longevity. Mech Ageing Dev. 2007;128:83–91.
  27. Bonafè M, Olivieri F. Genetic polymorphism in long-lived people: cues for the presence of an insulin/IGF-pathway-dependent network affecting human longevity. Mol Cell Endocrinol. 2009;299(1):118–23.
  28. Fontana L. Modulating human aging and age-associated diseases. Biochimica and Biophysica Acta. 2009;1790:1133–8.
  29. Licastro F, Candore G, Lio D, Porcellini E, Colonna-Romano G, Franceschi C, et al. Innate immunity and inflammation in ageing: a key for understanding age-related diseases. Immun Ageing. 2005;2(8):1–14.
  30. Zappulla D. Environmental stress, erythrocyte dysfunctions, inflammation, and the metabolic syndrome: adaptations to CO2 increases? J Cardiometab Syndr. 2008;3(1):30–4.
  31. Dandona P, Aljada A, Bandyopadhyay. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunl. 2004;25(1):4–7.
  32. Sun Q, Yue P, Deiuliis JA, Lumeng CN, Kampfrath T, Mikolaj MB, et al. Ambient air pollution exaggerates adipose inflammation and insulin resistance in a mouse model of diet-induced obesity. Circulation. 2009;119:538–46.
  33. Antuna-Puente B, Feve B, Fellahi S, Bastard J-P. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab. 2008;34(1):2–11.
  34. Salminen A, Kaarniranta K. Insulin/IGF-1 paradox of aging: regulation via AKT/IKK/NF-kB signaling. Cellular Signalling 2009, in press.
  35. Salminen A, Kaarniranta K. NF-kB Signaling in the aging process. J Clin Immunol. 2009;29:397–405.
  36. Li Y, Wang W-J, Cao H, Lu J, Wu C, Hu F-Y, et al. Genetic association of FOXO1A and FOXO3A with longevity in Han Chinese populations. Hum Mol Genet. 2009;18(24):4897–904.
  37. Willcox BJ, Donlon TA, He Q, Chen R, Grove JS, Yano K, et al. FOXO3A genotype is strongly associated with human longevity.Proc Natl Acad Sci. 2008;105(37):13987–92.
  38. Flachsbart F, Caliebe A, Kleindorp R, Blanche H, von Eller-Eberstein H, Nikolaus S, et al. Association of FOXO3A variation with human longevity confirmed in German centenarians. Proc Natl Acad Scie. USA 2009;106:2700–5.
  39. Anselmi CV, Malovini A, Roncarati R, Novelli V, Villa F, Condorelli G, et al. Association of the FOXO3A locus with extreme longevity in a southern Italian centenarian study. Rejuventation Res. 2009;12:95–104.
  40. Bonafe M, Barbieri M, Marchegiani F, Olivieri F, Ragno E, Giampieri C, et al. Polymorphic variants of insulin-like growth factor I (IGF-I) receptor and phosphoinositide 3-kinase genes affect IGF-I plamsa levels and human longevity: cues for an evolutionarily conserved mechanism of life span control. J Clin Endocrinol Metab. 2003;88(7):3299–304.
  41. Kojima T, Kamei H, Aizu T, Arai Y, Takayama M, Nakazawa S, et al. Association analysis between longevity in the Japanese population and polymorphic variants of genes involved in insulin and insulin-like growth factor I signaling pathways. Exp Gerontol. 2004;39(11-12):1595–8.
  42. Kuningas M, Magi R, Westendorp RG, Slagboom PE, Remm M, van Heemst D. Haplotypes in the human Foxo1a and Foxo3a genes; impact on disease and mortality at old age. Eur J Hum Genet. 2007;15(3):294–301.
  43. Lunetta K, D’Agostino Sr RB, Karasik D, Benjamin EJ, Guo C-Y, Govindaraju R, et al. Genetic correlates of longevity and selected age-related phenotypes: a genome-wide association study in the Framingham Study. BMC Medical Genetics. 2007;8(Suppl 1):S13.
  44. Gross DN, van den Heuvel APJ, Birnbaum MJ. The role of FoxO in the regulation of metabolism. Oncogene. 2008;27:2320–36.
  45. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 2004;303:2011–5.
  46. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W, et al. Mammalian SIRT1 represses forkhead transcription factors. Cell. 2004;116:551–63.
  47. Langley E, Pearson M, Faretta M, Bauer UM, Frye RA, Minucci S, et al. Human SIR2 deacetylases p53 and antagonizes PML/p53-induced cellular senescence. Embo J. 2002;21:2383–96.
  48. Wolf G. Calorie restriction increases life span: a molecular mechanism. Nutr Rev. 2006;64:89–92.
  49. Brook RD, Franklin B, Cascio W, Hong Y, Howard G, Lipsett M, et al. Air pollution and cardiovascular disease: a statement for healthcare professionals from the Expert Panel on Population Science of the American Heart Association. Circulation. 2004;109:2655–71.
  50. Bhatnagar A. Environmental cardiology: studying mechanistic links between pollution and heart disease. Circ Res. 2006;99:692–705.
  51. Pope CA 3rd, Burnett RT, Thurston GD, Thun MJ, Calle EE, Krewski D, et al. Cardiovascular mortality and long-term exposure to particulate air pollution: epidemiological evidence of general pathophysiological pathways of disease. Circulation. 2004;109:71–7.
  52. Miller KA, Siscovick DS, Sheppard L, Shepherd K, Sullivan JH, Anderson GL, et al. Long-term exposure to air pollution and incidence of cardiovascular events in women. N Engl J Med. 2007;356:447–58.
  53. Brook RD, Jerret M, Brook JR, Bard RL, Finkelstein MM. The relationship between diabetes mellitus and traffic-related air pollution. J Occup Environ Med. 2008;50:32–8.
  54. Chen JC, Schwartz J. Metabolic syndrome and inflammatory responses to long-term particulate air pollutants. Environ Health Perspect. 2008;116:612–7.
  55. Van Eeden SF, Ran WC, Suwa T, Mukae H, Terashima T, Fuji T, et al. Cytokines involved in the systemic inflammatory response induced by exposure to particulate matter air pollutants (PM10) Am J Respir Crit Care Med. 2001;164:826–30.
  56. Pope CA 3rd, Dockery DW. Health effects of fine particulate air pollution: lines that connect. J Air Waste Manag Assoc. 2006;56(6):709–42.
  57. Utell MJ, Frampton MW, Zareba W, Devlin RB, Cascio WE. Cardiovascular effects associated with air pollution: potential mechanisms and methods of testing. Inhal Toxicol. 2002;14(12):1231–47.
  58. O’Neill MS, Veves A, Zanobetti A, Sarnat JA, Gold DR, Economides PA, et al. Diabetes enhances vulnerability to particulate air pollution-associated impairment in vascular reactivity and endothelial function. Circulation. 2005;111:2913–20.
  59. O’Neill MS, Veves A, Sarnat JA, Zanobetti A, Gold DR, Economides PA, et al. Air pollution and inflammation in type 2 diabetes: a mechanism for susceptibility. Occup Environ Med. 2007;64:373–9.
  60. Knuckles TL, Dreher KL. Fine oil combustion particle bioavailable constituents induce molecular profiles of oxidative stress, altered function, and cellular injury in cardiomyocytes. J Toxicol Environ Health A. 2007;70:1824–37.
  61. Liang J, Slingerland JM. Multiple roles of the PI3/PKB (Akt) pathway in cell cycle progression. Cell Cycle. 2003;2:339–45.
  62. Zhang J, Ghio AJ, Gao M, Wei K, Rosen GD, Upadhyay D. Ambient particulate matter induces alveolar arrest: role of G1 cyclins. FEBS Lett. 2007;581:5315–20.
  63. Imboden M, Schwartz J, Schindler C, Curjuric I, Berger W, Liu SL, et al.; SAPALDIA Team. Decreased PM10 exposure attenuates age-related lung function decline: genetic variants in p53, p21, and CCND1 modify this effect.Environ Health Perspect. 2009;117(9):1420–7.
  64. Ceschi M, Sun CL, Van Den Berg D, Koh WP, Yu MC, Probst-Hensch N.The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore. Carcinogenesis. 2005;26(8):1457–64.
  65. Probst-Hensch NM, Sun CL, Van Den Berg D, Ceschi M, Koh WP, Yu MC.The effect of the cyclin D1 (CCND1) A870G polymorphism on colorectal cancer risk is modified by glutathione-S-transferase polymorphisms and isothiocyanate intake in the Singapore Chinese Health Study.Carcinogenesis. 2006;27(12):2475–82.
  66. Palmer LJ. UK Biobank: bank on it. Lancet. 2007;369:1980–2.
  67. Davis RL, Khoury MJ. The emergence of biobanks: practical design considerations for large population-based studies of gene-environment interactions. Community Genet. 2007;10:181–5.
  68. Hunter DJ, Khoury MJ, Drazen JM. Letting the genome out of the bottle-will we get our wish? N Engl J Med. 2008;358(2):105–7.
  69. Boffetta P. Exploring a cancer biomarker: the example of c-reactive protein. JNCI. 2010;102:142–4.
  70. Garcia-Closas M, Malats N, Silverman D, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet. 2005;366:649–59.
  71. Senn O, Russi EW, Imboden M, Probst-Hensch NM. Alpha1-antitrypsin deficiency and lung disease: risk modification by occupational and environmental inhalants. Eur Resp J. 2005; 26:1–9.
  72. Eleftherohorinou H, Wright V, Hoggart C, Hartikainen A-L, Jarvelin M-R, Balding D, et al. Pathway analysis of GWAS provides new insights into genetic susceptibility to 3 inflammatory diseases. PLoS One. 2009;4(11):e8068.
  73. O’Dushlaine C, Kenny E, Heron E, Segurado R, Gill M, Morris DW, Corvin A. The SNP ratio test: pathway analysis of genome-wide association datasets. Bioinformatics. 2009;25(20):2762–3.
  74. Yu K, Li Q, Bergen AW, Pfeffer RM, Rosenberg P, Caporaso N, Kraft P, Chatterjee N. Pathway analysis by adaptive combination of p-values. Genet Epidemiol. 2009;33(8):700–9.
  75. Campbell T, Campbell A. Emerging disease burdens and the poor in cities of the developing world. J Urban Health. 2007;84:154–64.
  76. Pan WH, Yeh WT, Weng LC. Epidemiology of metabolic syndrome in Asia. Asia Pac J Clin Nutr. 2008;17(Suppl 1):37–42.
  77. Whincup PH, Kaye SJ, Owen CG; et al. Birth weight and risk of type 2 diabetes: a systematic review. JAMA. 2008;300(24):2886–97.

Most read articles by the same author(s)